A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
ASP3082 grabs some early attention among degraders set to feature at ESMO.
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
The FDA throws out the company’s second attempt at an accelerated approval.